Summary
The influence of experimental rhinitis on the absorption of buserelin, measured as the serum luteinizing hormone (LH) response, has been investigated. A single dose of 200 µg buserelin was given to 24 healthy male volunteers after induction of experimental rhinitis with histamine and after use of a saline spray (placebo control).
Except on one occasion, when the pump-spray apparently was incorrectly operated, serum LH concentration rose after buserelin. There was no difference in the LH response between histamine-induced rhinitis and saline controls.
It was concluded that intranasal application of buserelin represents a reliable mode of application and that modification of the administration route or a change in the dosage schedule during naturally-occurring nasal inflammations, such as the common cold and allergic rhinitis, is unnecessary in patients undergoing chronic treatment with intranasal buserelin, e.g. for prostatic cancer, endometriosis, precocious puberty, and contraception.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lemay A, Quesnel G (1982) Potential new treatment of endometriosis: Reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. Fertil Steril 38: 376–379
Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA (1984) Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LHRH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41: 863–871
Shaw RW, Fraser HM, Boyle H (1983) Intranasal treatment with luteinizing hormone releasing hormone agonist in women with endometriosis. Br Med J 287: 1667–1669
Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas ATA, Comaru-Schally AM, Schally AV (1982) Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonist. Med Sci 79: 1658–1662
Faure N, Lemay A, Laroche B, Robert G, Plante R, Jean C, Thabet M, Roy R, Fazekas ATA (1983) Preliminary results on the clinical efficacy and safety of androgen inhibition by a LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. Prostate 4: 601–624
Wenderoth UK, Jacobi GH (1985) Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular GN-RH analogue treatment. In: Schroeder FH, Richards B (eds) OERTC Genito-urinary Group Monograph 2, part A: Therapeutic principles in metastatic prostatic cancer. Alan R Liss, New York pp 297–305
Klijn JG, de Jong FH (1982) Treatment with a luteinising-hormone releasing-hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1: 1213–1216
Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein AM (1985) LH-RH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873
Luder AS, Holland FJ, Costigan DC, Jenner MR, Wielgosz G, Fazekas ATA (1984) Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 58: 966–972
Nillius SJ, Bergquist C, Wide L (1978) Inhibition of ovulation in women by chronic treatment with a stimulatory LHR analogue — a new approach to birth control? Contraception 17: 537–545
Schmidt-Gollwitzer M, Hardt W, Schmidt-Gollwitzer K, von der Ohe M, Nevinny-Stickel J (1981) Influence of the LHRH analogue buserelin in cyclic ovarian function and on endometrium. A new approach to fertility control? Contraception 23: 187–195
Sandow J, Clayton RN, Kuhl H (1981) Pharmacology of LHRH and its analogues. In: Crosignani PG, Rubin BL (eds) Endocrinology of human infertility: New aspects. Academic Press, London, pp 221–246
Borgmann V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R (1982) Sustained suppression of testosterone production by the luteinizing hormone releasing hormone agonist buserelin in patients with advanced prostate carcinoma: A new therapeutic approach. Lancet 1: 1097–1099
Petri W, Seidel R, Sandow J (1984) A pharmaceutical approach to long-term therapy with peptides. In: Labrie F, Belanger A, Dupont A (eds) LHRH and its analogues. Busic and clinical aspects. The Netherlands: Elsevier B. V., Amsterdam, pp 63–76
Lawrence JR, McEwen J, Pidgen AW, Robinson JD (1981) Dose response characteristics of D-ser (TBU)6-Des gly10-LHRH-ethylamide (HOE 766 — Buserelin) following intranasal administration to five healthy male volunteers. Br J Clin Pharmacol 13: 297P-298P
Secher C, Kirkegaard J, Borum P, Maansson A, Osterhammel P, Mygind N (1982) Significance of H1- and H2-receptors in the human nose: Rationale for use of combined preparations. J Allergy Clin Immunol 70: 211–218
Broms P, Ivarsson A, Jonson B (1982) Rhinomanometry I — Simple equipment. Acta Otolaryngol (Stockh) 93: 455–460
Broms P, Jonson B, Lamm CJ (1982) Rhinomanometry II — A system for numerical description of nasal airway resistance. Acta Otolaryngol (Stockh) 94: 157–168
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Larsen, C., Jørgensen, M.N., Tommerup, B. et al. Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin. Eur J Clin Pharmacol 33, 155–159 (1987). https://doi.org/10.1007/BF00544560
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544560